NASDAQ:NCNA

NuCana Q3 2025 Earnings Results & Report

NuCana logo
$0.88 +0.02 (+1.96%)
Closing price 03:55 PM Eastern
Extended Trading
$0.87 -0.01 (-0.80%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

NuCana beat analyst earnings expectations in its Q3 2025 results, released November 13, 2025. The company reported EPS of -$0.10 versus the -$2.6884 consensus estimate.

Earnings Announcement Details

Quarter
Q3 2025
Time
Before Market Opens

NuCana EPS Results

Actual EPS
-$0.10
Consensus EPS
-$2.6884
Beat/Miss
Beat by +$2.5884
One Year Ago EPS
N/A
EPS Beat Rate
5 of last 5 quarters

NuCana Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

NuCana Q3 2025 Earnings FAQ

NuCana (NASDAQ:NCNA) reported earnings of -$0.10 per share for Q3 2025, beating the consensus estimate of -$2.6884. The report was announced on Thursday, November 13, 2025.

NuCana Earnings Headlines

Bitcoin's problem is its own size
Bitcoin is trading near $60,000. For your Bitcoin position to double from here, roughly $1.5 trillion in new money has to flow into a single asset. Not impossible. Now ask what it takes to move a coin with a $40 million market cap. Not a trillion dollars. A fraction of a percent of one. That's the entire reason my team stopped hunting for the next Bitcoin years ago. I put together a short presentation walking through where we're looking instead, and why the largest percentage moves in this market stopped coming from the coins everyone recognizes.tc pixel
NuCana plc Sponsored ADR
See More NuCana Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like NuCana? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NuCana and other key companies, straight to your email.

About NuCana

NuCana (NASDAQ:NCNA) is a clinical-stage biopharmaceutical company based in Edinburgh, Scotland, that develops investigational medicines for cancer. Its research focuses on nucleotide analogues, a class of compounds used in some cancer treatments.

The company’s ProTide platform is designed to improve how these compounds enter cells and become active. NuCana’s development programs have included NUC-3373, an investigational fluoropyrimidine, and NUC-7738, an investigational adenosine analogue, as well as NUC-1031, an earlier candidate.

NuCana’s work is centered on developing and evaluating potential cancer therapies; its drug candidates are investigational and have not been established as approved treatments.

View NuCana Profile